Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
Search
Respimat media
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Mareks Disease Poultry Chicken
Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.
International Postdocs realize their potential in Biberach
Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
European Commission grants marketing authorization for spesolimab, the first specific treatment option for generalized pustular psoriasis flares in adults
Our Partners Harvard
Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
Our Partners Bioharmony
Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
Netherton Syndrome
Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Fremont
Upstream process development in a high throughput automated bioreactor system.
Maria Weber
Lead Patient Safety Physician Maria Weber tells us about why she joined Boehringer Ingelheim, and the importance of patient centricity in everything she does.
Duluth
Duluth
Our people
Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
Be At The Heart Of Every Breakthrough
Now is the time to cultivate your unique tech talent at a leading pharmaceutical company.
More Green Overview
Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
The Core of our Leitbild
Who we are and what we strive for
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Koropi
For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.
Immuno-Oncology
We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Daniel Kiesenhofer
Diverse, caring, collaborative - Daniel Kiesenhofer on Boehringer Ingelheim